对去势抵抗性前列腺癌（CRPC）患者使用卡巴他赛需要事先进行多西他赛治疗。由于多西紫杉醇相关的副作用，序贯化疗可能必须停止。本研究调查了多西他赛和卡巴他赛的治疗结果与其相关副作用之间的关系。我们回顾性分析了 2014 年 10 月至 2022 年 6 月期间在丰中市立医院接受多西他赛联合或不联合卡巴他赛治疗的 69 名 CRPC 患者。28 名患者 (41%) 由于副作用而停用多西他赛，多西他赛周期中位数为终止次数为 2（范围：1-11）。其中 14 名患者在多西紫杉醇治疗后未接受任何治疗。 28 例因副作用而停用多西紫杉醇的患者与 41 例未发现化疗周期总数（2.5 vs 9；P＜0.001）和治疗失败时间（56 天 vs 301 天）的患者的比较天；P＝0.001)，从多西紫杉醇治疗开始，总生存期有缩短的趋势(259 天 vs 512 天；P＝0.06)。多变量分析表明，由于副作用（OR＝0.07；P＜0.001）和血红蛋白降低（OR＝0.01；P＝0.001）而停用多西他赛是抑制卡巴他赛引入的重要因素。减少多西他赛的副作用，包括早期药物转换，可能会让更多的 CRPC 患者接受卡巴他赛治疗。因此，基于紫杉烷的化疗可能有助于额外的生存优势。

The administration of cabazitaxel for patients with castration-resistant prostate cancer (CRPC) requires prior docetaxel therapy. Sequential chemotherapy may have to be discontinued due to docetaxelassociated side effects. This study investigated the relationship between treatment outcome of docetaxel and cabazitaxel and their associated side effects. We retrospectively analyzed 69 patients with CRPC who had been administered docetaxel withand without subsequent cabazitaxel at Toyonaka Municipal Hospital from October 2014 to June 2022. Twenty-eight patients (41%) discontinued docetaxel because of side effects, and the median number of docetaxel cycles at discontinuation was 2 (range : 1-11). Fourteen of these patients received no treatment following docetaxel. A comparison of the 28 patients who had discontinued docetaxel due to side effects with 41 patients who had not revealed a significant difference in the total numbers of chemotherapy cycles (2.5 vs 9 ; P＜0.001) and time to treatment failure (56 days vs 301 days ; P＝ 0.001), with a trend toward shorter overall survival from the start of docetaxel treatment (259 days vs 512 days ; P＝0.06). Multivariate analysis identified discontinuation of docetaxel due to side effects (OR＝0.07 ; P＜0.001) and lower hemoglobin (OR＝0.01 ; P＝0.001) as significant factors inhibiting the introduction of cabazitaxel. Reducing the side effects of docetaxel, including early drug switching, may allow more CRPC patients to be reached with cabazitaxel. Consequently, the resulting taxane-based chemotherapy may contribute to an additional survival advantage.